Hutchison MediPharma (HMP) has started a Phase I clinical trial of sulfatinib (HMPL-012) to treat patients with advanced solid tumours.

Earlier this year, the US Food and Drug Administration (FDA) cleared the investigational new drug (IND) application for sulfatinib.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

HMP is also planning two Phase III studies for neuroendocrine tumours (NET) and a Phase Ib trial in China for the treatment of thyroid cancer.

"NET responses to sulfatinib have been observed to improve gradually with time."

Taking place in the US, the Phase I dose escalation trial is designed to evaluate the safety and tolerability of sulfatinib.

A Phase II trial for NET is expected to begin after Phase I concludes.

Sulfatinib inhibits tyrosine kinase activity associated with the vascular endothelial growth factor receptor (VEGFR) and fibroblast growth receptor (FGFR). The latter is a receptor for a protein which plays a role in tumour growth.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

In a Phase I trial in China, sulfatinib’s objective response rate among 18 NET patients was 44.4%.

Sunitinib and everolimus, the two approved single agent therapies for pancreatic NET, achieved objective response rates of less than 10% in their pivotal clinical trials.

In addition, NET responses to sulfatinib have been observed to improve gradually with time.

It is claimed that sulfatinib is HMP’s first oncology candidate to be taken through proof-of-concept in China, and expanded to a US clinical trial, without a partner.

Apart from the US Phase I trial, HMP is in the process of initiating four clinical trials in China.

Last October, the company started a multicentre, single-arm, open-label Phase Ib/II trial in broad spectrum NET patients in China.

This trial evaluated the efficacy, safety, tolerability, and pharmacokinetic characteristics of sulfatinib.

So far, the Phase Ib results appear in line with positive results from the Phase I trial.